Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.56 |
| ▸ | CA2 | P00918 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.55 |
| ▸ | LPL | P06858 | 11/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.55 |
| ▸ | F11 | P03951 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2572162 | 0.96 | CA1 (0.60) | CA1CA2CA9LIPGLPL | |
| SCHEMBL1284019 | 0.84 | CA1 (0.60) | CA1CA2CA9LIPGLPL | |
| SCHEMBL1684672 | 0.81 | CA1 (0.61) | CA1CA2CA9LIPGLPL | |
| SCHEMBL16881568 | 0.81 | CA1 (0.57) | CA1CA2CA9LIPGLPL | |
| SCHEMBL30693702 | 0.81 | CA1 (0.70) | CA1CA2CA9LIPGLPL | |
| SCHEMBL5675802 | 0.80 | NPC1 (0.62) | CA1CA2CA9LIPGLPL | |
| SCHEMBL21197913 | 0.79 | CA1 (0.55) | CA1CA2CA9LIPGLPL | |
| SCHEMBL9888401 | 0.79 | LIPG (0.58) | CA1CA2CA9LIPGLPL | |
| SCHEMBL12523750 | 0.79 | LIPG (0.53) | CA1CA2CA9LIPGLPL | |
| SCHEMBL15252314 | 0.79 | CA1 (0.55) | CA1CA2CA9LIPGLPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | CA1 4836/4885CA2 4667/4885CA9 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.